Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions

J Dermatol Sci. 2012 Dec;68(3):199-202. doi: 10.1016/j.jdermsci.2012.09.002. Epub 2012 Sep 21.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Biomarkers / metabolism
  • Fatty Acid-Binding Proteins / blood
  • Fatty Acid-Binding Proteins / metabolism*
  • Female
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Psoriasis / blood
  • Psoriasis / metabolism*
  • Psoriasis / radiotherapy
  • Psoriasis / therapy*
  • Skin / metabolism
  • Ultraviolet Therapy

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • FABP5 protein, human
  • Fatty Acid-Binding Proteins
  • Infliximab
  • Adalimumab